Reinvesting the cellular properties of human amniotic epithelial cells and their therapeutic innovations

Jing Yang; Jing Yang; Jing Yang; Yuefeng Lu; Yuefeng Lu; Yuefeng Lu; Jinping Zhao; Jinping Zhao; Jinping Zhao; Yi Luo; Yi Luo; Yi Luo; Wangping Hao; Wangping Hao; Wangping Hao; Wencheng Zhang; Wencheng Zhang; Wencheng Zhang; Wencheng Zhang; Zhiying He; Zhiying He; Zhiying He; Zhiying He

doi:10.3389/fimmu.2024.1466529

Frontiers in Immunology (Oct 2024)

Reinvesting the cellular properties of human amniotic epithelial cells and their therapeutic innovations

Jing Yang,
Jing Yang,
Jing Yang,
Yuefeng Lu,
Yuefeng Lu,
Yuefeng Lu,
Jinping Zhao,
Jinping Zhao,
Jinping Zhao,
Yi Luo,
Yi Luo,
Yi Luo,
Wangping Hao,
Wangping Hao,
Wangping Hao,
Wencheng Zhang,
Wencheng Zhang,
Wencheng Zhang,
Wencheng Zhang,
Zhiying He,
Zhiying He,
Zhiying He,
Zhiying He

Affiliations

Jing Yang: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Jing Yang: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Jing Yang: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Yuefeng Lu: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Yuefeng Lu: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Yuefeng Lu: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Jinping Zhao: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Jinping Zhao: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Jinping Zhao: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Yi Luo: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Yi Luo: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Yi Luo: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Wangping Hao: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Wangping Hao: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Wangping Hao: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Wencheng Zhang: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Wencheng Zhang: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Wencheng Zhang: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Wencheng Zhang: Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, China
Zhiying He: Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Zhiying He: Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Zhiying He: Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, China
Zhiying He: Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, China

DOI: https://doi.org/10.3389/fimmu.2024.1466529
Journal volume & issue: Vol. 15

Abstract

Read online

Human amniotic epithelial cells (hAECs) have shown promising therapeutic effects in numerous studies on various diseases due to their properties such as low immunogenicity, immunomodulation, paracrine effect, and no teratoma formation in vivo. Nevertheless, there are still many problems in archiving the large-scale clinical application of hAECs, ranging from the vague definition of cell properties to the lack of clarification of the motion of actions in cell therapies, additionally, to the gap between cell quantities with limited proliferation capacity. This review provides a detailed overview of hAECs in the aspects of the lineage development of amniotic epithelial cell, cell characteristics and functional roles, ex vivo cell cultivation and expansion systems, as well as their current status and limitations in clinical applications. This review also discusses the advantages, limitations and feasibility of hAECs, and anticipates their prospects as cell therapy products, with the aim of further promoting their clinical applications.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords